ForPatients
by Roche

Spinal Muscular Atrophy (SMA)

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7034067 (RG7916) Given by Mouth in Healthy Volunteers

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT02633709 2015-004605-16 BP29840

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The objective of this study is to assess the safety and tolerability of Risdiplam (RO7034067) in healthy people. The study will assess what the body does to Risdiplam (RO7034067) and what Risdiplam (RO7034067) does to the body. Risdiplam (RO7034067) will be given by mouth in gradually increasing doses. The data from this study will help to define the dose to further explore Risdiplam (RO7034067) in patients with Spinal Muscular Atrophy.

Hoffmann-La Roche	Phase 1
Sponsor	Phase

NCT02633709 2015-004605-16 BP29840
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
Male	>= 18 Years & <= 45 Years	Accepts Healthy Volunteers